Manhattan Genomics has set its sights on creating the first legally - recognized sexless babies in the United States. It intends to achieve this by employing gene - editing techniques on human embryos to prevent genetic diseases, thereby breathing new life into concepts aimed at halting the transmission of inherited disorders.

At present, U.S. law places strict limitations on the clinical application of gene - edited embryos. However, there is a faction of government advisors who are showing a keen interest in reproductive technologies. Manhattan Genomics has made it clear that it will strictly adhere to regulatory recommendations. Initially, the company will carry out research on animal models.

The company's research is mainly centered on single - gene diseases, such as Huntington's disease. It firmly believes that embryo gene - editing technology holds immense potential for alleviating human suffering. It's worth noting that CRISPR technology is not without its flaws; it has "off - target effects." In light of this, Manhattan Genomics has a well - thought - out plan. First, it will conduct tests to assess the safety and precision of various CRISPR variants in mice. Subsequently, it will move on to primates. Only after years of technological refinement and maturation will the company consider initiating human clinical trials.